Biohacking
Oura's IPO filing reveals what the ring does not yet do
By Life and Health Today Staff, . Life and Health Today.
Oura filed to go public this fall, according to Quantified Self, which reviewed the company's submission to the Securities and Exchange Commission. The filing reported revenue of roughly $500 million for 2024, up from about $200 million the year before, and said the company has sold more than 2.5 million rings to date.
The part of the business Oura points investors toward is not ring sales. It is the $5.99 monthly subscription members pay to see their own health scores. Subscription revenue is recurring, carries high margins, and grows without the company shipping another unit. That is the financial story the filing tells.
The more interesting story for anyone wearing the ring is what Oura says it is working toward. According to Quantified Self's reading of the filing, the company describes a research pipeline aimed at illness onset detection, blood glucose pattern tracking, and cardiovascular measures. Those are meaningful targets. Early illness detection and continuous glucose insight are things a lot of people would pay for.
Here is the sentence that matters most: none of it is cleared by the FDA as a diagnostic today. The filing says so itself, listing regulatory classification as a risk factor for investors. That is not a small footnote. FDA clearance as a diagnostic is the line between a device that can tell you something is wrong and a device that can show you an interesting pattern. The ring is currently on the pattern side of that line.
What this does not mean is that the tracking the ring does now is worthless. Sleep staging, resting heart rate, heart rate variability, body temperature trends, and activity data are real measurements with real uses. But there is a gap between "tracks a pattern" and "detects a condition," and that gap is exactly what the FDA process is designed to evaluate. Until Oura clears that process for a specific claim, the ring cannot make that claim, and neither can the people selling it to you.
The competitive argument Oura makes in the filing is about data depth, according to Quantified Self. A member who has worn the ring for three years has a personal baseline that a new competitor cannot reproduce. The algorithms are trained on an aggregate of those individual baselines. That is a real structural advantage if the underlying measurements turn out to be clinically meaningful, and a less meaningful one if they do not. The value of the moat depends entirely on what the data is eventually shown to predict.
What the filing cannot tell you, and what the Quantified Self piece does not claim to know, is whether the research pipeline will produce results that satisfy regulators. Getting from "we are studying blood glucose patterns" to "FDA-cleared glucose monitor" is a long road, and most devices that start down it do not finish. That is not a prediction about Oura specifically. It is the base rate.
If you are wearing the ring now, the honest answer is that you are using a well-reviewed sleep and recovery tracker with ambitious plans attached to it. Whether those plans become cleared diagnostics is a question for regulators, not for the IPO filing. Anyone deciding whether the ring is worth their money or their hope should keep that distinction in front of them.